Literature DB >> 21577233

Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.

E S Antonarakis1, A J Armstrong.   

Abstract

Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21577233      PMCID： PMC4124621          DOI： 10.1038/pcan.2011.24

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN： 1365-7852            Impact factor:   5.554


  90 in total

Review 1.  Targeting the PI3K/AKT pathway for the treatment of prostate cancer.

Authors:  Debashis Sarker; Alison H M Reid; Timothy A Yap; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

2.  Genetic alterations in the PI3K pathway in prostate cancer.

Authors:  Xiuju Sun; Jian Huang; Taku Homma; Daisuke Kita; Helmut Klocker; Georg Schafer; Peter Boyle; Hiroko Ohgaki
Journal:  Anticancer Res       Date:  2009-05       Impact factor: 2.480

3.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

4.  Phase II study of sunitinib in men with advanced prostate cancer.

Authors:  M Dror Michaelson; M M Regan; W K Oh; D S Kaufman; K Olivier; S Z Michaelson; B Spicer; C Gurski; P W Kantoff; M R Smith
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

Review 5.  The role of Src in solid tumors.

Authors:  Deric L Wheeler; Mari Iida; Emily F Dunn
Journal:  Oncologist       Date:  2009-07-06

6.  Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

Authors:  Jeanny B Aragon-Ching; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Seth M Steinberg; David Draper; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg; William L Dahut
Journal:  BJU Int       Date:  2009-01-09       Impact factor: 5.588

7.  Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.

Authors:  Claudio Festuccia; Giovanni Luca Gravina; Anna Maria D'Alessandro; Paola Muzi; Danilo Millimaggi; Vincenza Dolo; Enrico Ricevuto; Carlo Vicentini; Mauro Bologna
Journal:  Endocr Relat Cancer       Date:  2009-01-19       Impact factor: 5.678

8.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

9.  Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.

Authors:  Taroh Satoh; Isamu Okamoto; Masaki Miyazaki; Ryotaroh Morinaga; Asuka Tsuya; Yoshikazu Hasegawa; Masaaki Terashima; Shinya Ueda; Masahiro Fukuoka; Yutaka Ariyoshi; Toshikazu Saito; Noriyuki Masuda; Hirokazu Watanabe; Tetsuo Taguchi; Toru Kakihara; Yumiko Aoyama; Yohko Hashimoto; Kazuhiko Nakagawa
Journal:  Clin Cancer Res       Date:  2009-05-26       Impact factor: 13.801

10.  Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.

Authors:  Per Björk; Anders Björk; Thomas Vogl; Martin Stenström; David Liberg; Anders Olsson; Johannes Roth; Fredrik Ivars; Tomas Leanderson
Journal:  PLoS Biol       Date:  2009-04-28       Impact factor: 8.029
View more
  11 in total

1.  Abiraterone acetate for prostate cancer: a new era of hormonal therapies.

Authors:  Emmanuel S Antonarakis
Journal:  Asian J Androl       Date:  2011-07-11       Impact factor: 3.285

2.  The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients.

Authors:  Carole Alison Chrvala
Journal:  P T       Date:  2012-08

3.  The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells.

Authors:  Kohei Hashimoto; Yuki Kyoda; Toshiaki Tanaka; Toshihiro Maeda; Ko Kobayashi; Kohsuke Uchida; Hiroshi Kitamura; Koichi Hirata; Taiji Tsukamoto; Naoya Masumori
Journal:  Lab Invest       Date:  2015-01-12       Impact factor: 5.662

4.  The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.

Authors:  Jatinder Goyal; Philipp Nuhn; Peng Huang; Prachi Tyagi; Daniel Oh; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis
Journal:  BJU Int       Date:  2012-06-15       Impact factor: 5.588

Review 5.  Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.

Authors:  Andrew J Armstrong; Mario A Eisenberger; Susan Halabi; Stephane Oudard; David M Nanus; Daniel P Petrylak; A Oliver Sartor; Howard I Scher
Journal:  Eur Urol       Date:  2011-11-12       Impact factor: 20.096

Review 6.  Novel therapies for the treatment of advanced prostate cancer.

Authors:  J M Clarke; A J Armstrong
Journal:  Curr Treat Options Oncol       Date:  2013-03

7.  Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.

Authors:  Philipp Nuhn; Ajay M Vaghasia; Jatinder Goyal; Xian C Zhou; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis
Journal:  BJU Int       Date:  2014-02-14       Impact factor: 5.588

8.  The unfolding treatment landscape for men with castration-resistant prostate cancer.

Authors:  Jenny J Kim; Daniel Keizman; Samuel R Denmeade; Emmanuel S Antonarakis
Journal:  Clin Investig (Lond)       Date:  2011-11

Review 9.  Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer.

Authors:  Nikolaos Pyrgidis; Ioannis Vakalopoulos; Petros Sountoulides
Journal:  Hormones (Athens)       Date:  2020-11-02       Impact factor: 2.885

10.  Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

Authors:  Bently P Doonan; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2015-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.